TAX2 peptide is a novel dodecapeptide designed through molecular docking and simulation, originating from the sequence of the cell surface receptor CD47. As a selective antagonist of the TSP-1 (thrombospondin-1) and CD47 interaction, TAX2 peptide enhances the binding of TSP-1 to CD36. This disrupts the activation of VEGFR2 (vascular endothelial growth factor receptor 2), blocking downstream NO (nitric oxide) signaling and exhibiting anti-angiogenic properties. TAX2 peptide is useful for studying angiogenesis and tumor cell interactions within the tumor microenvironment.